76 related articles for article (PubMed ID: 6140695)
1. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data.
Breyer-Pfaff U; Brinkschulte M; Rein W; Schied HW; Straube E
Pharmacopsychiatria; 1983 Sep; 16(5):160-5. PubMed ID: 6140695
[TBL] [Abstract][Full Text] [Related]
2. Prediction and evaluation criteria in perazine therapy of acute schizophrenics: psychopathological results.
Schied HW; Rein W; Straube E; Jung H; Breyer-Pfaff U
Pharmacopsychiatria; 1983 Sep; 16(5):152-9. PubMed ID: 6140694
[TBL] [Abstract][Full Text] [Related]
3. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Methodological considerations, sample population, and research variables.
Rein W; Schied HW; Breyer-Pfaff U; Straube E
Pharmacopsychiatria; 1983 Sep; 16(5):147-51. PubMed ID: 6140693
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between perazine serum concentration and clinical results in long-term treated schizophrenic outpatients (author's transl)].
Pietzcker A; Müller-Oerlinghausen B; Schley J; Chaskel H; Poppenberg A; Urban R
Arzneimittelforschung; 1978; 28(8):1302-3. PubMed ID: 37850
[TBL] [Abstract][Full Text] [Related]
5. Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine.
Gaebel W; Pietzcker A; Ulrich G; Schley J; Müller-Oerlinghausen B
Pharmacopsychiatry; 1988 Nov; 21(6):384-6. PubMed ID: 2907645
[No Abstract] [Full Text] [Related]
6. Autonomic nervous system differences as predictors of short-term outcome in schizophrenics.
Straube ER; Schied HW; Rein W; Breyer-Pfaff U
Pharmacopsychiatry; 1987 May; 20(3):105-10. PubMed ID: 2885864
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients].
Dieterle DM; Müller-Spahn F; Ackenheil M
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():18-22. PubMed ID: 1683334
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients].
Schmidt LG; Schüssler G; Kappes CV; Müller-Oerlinghausen B
Nervenarzt; 1982 Sep; 53(9):530-6. PubMed ID: 6127637
[No Abstract] [Full Text] [Related]
9. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
[TBL] [Abstract][Full Text] [Related]
10. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
11. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
12. Early serum levels of neuroleptics do not predict therapeutic response in schizophrenia.
Gaebel W; Müller-Oerlinghausen B; Schley J
Prog Neuropsychopharmacol Biol Psychiatry; 1992; 16(6):891-900. PubMed ID: 1355303
[TBL] [Abstract][Full Text] [Related]
13. [Zotepine versus perazine in patients with paranoid schizophrenia: a double-blind controlled trial of its effectiveness].
Wetzel H; von Bardeleben U; Holsboer F; Benkert O
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():23-9. PubMed ID: 1683336
[TBL] [Abstract][Full Text] [Related]
14. [Changes in drug elimination under the influence of perazine therapy (author's transl)].
Petruch F; Schüppel R; Breyer U
Arzneimittelforschung; 1976; 26(6):1154-5. PubMed ID: 9113
[TBL] [Abstract][Full Text] [Related]
15. Mesoridazine and thioridazine: clinical effects and blood levels in refractory schizophrenics.
Vital-Herne J; Gerbino L; Kay SR; Katz IR; Opler LA
J Clin Psychiatry; 1986 Jul; 47(7):375-9. PubMed ID: 2873133
[TBL] [Abstract][Full Text] [Related]
16. [Clinical effectiveness of zotepine in treatment of negative schizophrenic symptoms. Results of an open and a double-blind controlled trial].
Müller-Spahn F; Dieterle D; Ackenheil M
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():30-5. PubMed ID: 1683337
[TBL] [Abstract][Full Text] [Related]
17. [A differential effect profile of neuroleptic therapy of acute schizophrenic patients? Results of a clinico-naturalistic study].
Schmidt LG; Siemetzki H
Nervenarzt; 1988 Dec; 59(12):721-6. PubMed ID: 2905770
[No Abstract] [Full Text] [Related]
18. An open study of risperidone liquid in the acute phase of schizophrenia.
Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
[TBL] [Abstract][Full Text] [Related]
19. Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients.
Pietzcker A; Poppenberg A; Schley J; Müller-Oerlinghausen B
Arch Psychiatr Nervenkr (1970); 1981; 229(4):315-29. PubMed ID: 6111989
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder.
Ulrich S; Neuhof S; Braun V; Meyer FP
Pharmacopsychiatry; 1998 Sep; 31(5):163-9. PubMed ID: 9832347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
